34 results on '"Feyerabend S"'
Search Results
2. 1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
3. 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
4. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
5. 630P Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
6. 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
7. 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
8. 231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
9. 629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
10. 630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study
11. 624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
12. LBA13 - CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
13. PT127 - ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
14. 1038 - Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis
15. 1035 - Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
16. 810P - Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
17. 797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)
18. 928TiP - ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma
19. 1149P - Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
20. 803P - Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer
21. P081 - Prospective, non-interventional study on the influence of adherence measures on the therapy with Abiraterone Acetate (AA) + Prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma
22. P080 - SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC)
23. 746P - The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)
24. PCN296 - The Prostate Cancer Registry: Analysis of Medical Resource Utilisation (Mru) in An International, Prospective, Observational Study of Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
25. 755O - A Randomized Phase 3 Study Comparing First-Line Docetaxel/Prednisone (Dp) to Dp Plus Custirsen in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
26. O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®)
27. 429 PCR-based detection of circulating tumor cells in prostate cancer – preliminary experience
28. 76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
29. ANTI-INFLAMMATORY AND ANGIOSTATIC THERAPY IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
30. THE VALUE OF THE PCA3 SCORE IN GUIDING PROSTATE BIOPSY DECISION IN MEN WITH A PRIOR NEGATIVE BIOPSY
31. PCA3 REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY
32. 113 ANNEXIN A3 QUANTIFICATION FROM SUPERNATANTS OF URINE AFTER DRE PROVIDES A NOVEL AND CLINICALLY EASY AVAILABLE BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF PROSTATE CANCER
33. BONE TURNOVER PARAMETERS ICTP AND PINP ARE PROMISING SERUM MARKERS FOR DIAGNOSIS AND THERAPY MONITORING OF BONE METASTASES IN PROSTATE CANCER PATIENTS
34. 570Docetaxel, estramustine and prednisone for the treatment of hormone refractory prostate cancer: A single center experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.